Neuro-Oncology Reviews

Volume 28 Number 6
28 February 2026

Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 5, 28 February

Falcao V, Rego LHRM, Rodrigues PB, de Moraes FCA.
Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis.
J Neurooncol. 2026 Feb 21;177(1):13. doi: 10.1007/s11060-026-05462-1. PMID: 41721900˰ ˍ

Gonzales-Portillo D, Vashi B, Bains Williams K, Cervantes J.
Metformin Renders Survival Advantage to Patients with Glioblastoma Multiforme.
Neurol Int. 2026 Feb 24;18(3):40. doi: 10.3390/neurolint18030040. PMID: 41893042. ˍ

Bedrosian TA, Wong M, Heinzen EL, Deneen B, Christian-Hinman CA.
Merritt-Putnam Symposium | Tumor-Associated Epilepsy and Epilepsy-Associated Tumors: Exploring the Bidirectional Crosstalk Between Tumors and Seizures.
Epilepsy Curr. 2026 Feb 26:15357597261418332. doi: 10.1177/15357597261418332. PMID: 41768595. ˍ

Chen HC, Wong ET, Sarangi S, Elinzano H, Kuburich NA, Mani SA, Ali R, Cielo D, Svokos KA, Sampath P, Malik AN, Lee CK, Doberstein CE, Lawler SE, Seyhan A, El-Deiry WS, Chen CC.
Tumor antigen only (TAO) vaccine platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trials.
EClinicalMedicine. 2026 Feb 26;93:103774. doi: 10.1016/j.eclinm.2026.103774. PMID: 41783089. ˍ

Kisiel S, Pawlik M, Niemcewicz WJ, Janicki W, Świerczyńska J, Romanczuk K, Zdanowski R, Borkowska A.
From Cerebrovascular Injury to Brain Cancer: The Role of Blood-Brain Barrier Dysfunction.
Biomedicines. 2026 Feb 26;14(3):511. doi: 10.3390/biomedicines14030511. PMID: 41898158. ˍ

Kordyukova MY, Bulgakov TK, Sorokina MA, Kudryashova OM, Abakumova TO, Meshcheryakova VI, Grigoriev IV, Senko IV, Shevchenko EK, Belousov VV.
Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
Int J Mol Sci. 2026 Feb 26;27(5):2207. doi: 10.3390/ijms27052207. PMID: 41828436. ˍ

Wang P, Liu W, Zhou C.
Mapping knowledge landscapes and emerging trends in artificial intelligence in glioblastoma: A bibliometric analysis.
Digit Health. 2026 Feb 26;12:20552076261428356. doi: 10.1177/20552076261428356. PMID: 41767867. ˍ

Zhao H, Jiang Q, Wang Q, Wang Z, Huang Y, Lei T.
Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
Cells. 2026 Feb 26;15(5):409. doi: 10.3390/cells15050409. PMID: 41827842. ˍ

Hayat MA, Yu S, Tao G, Ghani MU, Hu J.
Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications.
Biochem Pharmacol. 2026 Feb 27;248:117851. doi: 10.1016/j.bcp.2026.117851. PMID: 41765112. ˍ

Salmeron-Moreno K, Papisetty K, Kim CD, McCaffery T, Kashlan R, Theodore J, Kim JM, Buclez J, Duggireddy H, Maldonado J, Guerrero-Cázares H, Pradilla G, Garzon-Muvdi T.
Neuro-Oncological Perspectives on Cancer Stem Cell Biology in Glioblastoma: Implications for Resection, Recurrence, Targeted Therapy, and Other CNS Tumors.
Cells. 2026 Feb 27;15(5):413. doi: 10.3390/cells15050413. PMID: 41827847. ˍ

Mishra P, Gupta P, Markowska A, Ghavami S, Markowski J, Łos MJ.
Advancements in Drug Delivery Systems in Glioblastoma Therapy.
Int J Mol Sci. 2026 Feb 28;27(5):2298. doi: 10.3390/ijms27052298. PMID: 41828518. ˍ